UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Lilly’s anticancer combo drug nears getting insurance benefit
Eli Lilly said its anticancer drug Verzenio showed an improvement in overal...
by Kim Yun-mi
|
2019-08-07 15:44
라인
Japanese firms fear boycott may hurt prescription drug sales
Korean offshoots of Japanese pharmaceutical companies are worrying that the...
by Kim Yun-mi
|
2019-08-06 15:44
라인
Roche, MSD, AstraZeneca: top 3 risers on NASDAQ biotech
Roche, MSD (Merck in the U.S.), and AstraZeneca achieved the most significa...
by Kim Yun-mi
|
2019-08-06 11:29
라인
Amgen’s lipid-lowering Repatha beats Sanofi’s Praluent in Q2 sales
Amgen won the battle against Sanofi in sales of cholesterol-lowering PCSK9 ...
by Kim Yun-mi
|
2019-08-05 15:37
라인
‘MSD Korea playing tricks to maintain monitoring on salespersons’
MSD Korea’s labor and management are again in dispute over the so-called “s...
by Kim Yun-mi
|
2019-08-02 15:48
라인
Conflict erupts between employees of Takeda, Shire during merger
Takeda Pharmaceutical Korea’s labor union said Takeda employees faced unfai...
by Kim Yun-mi
|
2019-08-02 14:23
라인
‘Recurrent chronic lymphocytic leukemia needs various treatment options’
Chronic lymphocytic leukemia (CLL) progresses more slowly than acute blood ...
by Kim Yun-mi
|
2019-08-01 15:31
라인
Novartis fails to expand heart failure drug Entresto’s indication
Novartis said its phase-3 Paragon-HF trial on heart failure treatment Entre...
by Kim Yun-mi
|
2019-07-31 14:26
라인
‘FDA likely to OK 11 blockbuster candidates in August’
The U.S. Food and Drug Administration (FDA) will likely approve 11 innovati...
by Kim Yun-mi
|
2019-07-29 16:55
라인
Takeda’s Zejula poised to change local ovarian cancer treatment market
Takeda’s Zejula (ingredient: niraparib) became eligible for an insurance be...
by Kim Yun-mi
|
2019-07-29 12:04
라인
Will Gilead enter the autoimmune diseases market?
Gilead Sciences is highly likely to buy Otezla (apremilast), a new oral PDE...
by Kim Yun-mi
|
2019-07-22 17:34
라인
Employees file suit against Galderma Korea
Galderma Korea has recently been sued by its labor union. The company’s lab...
by Kim Yun-mi
|
2019-07-19 15:41
라인
2 cancer immunotherapy makers face different situations in reimbursement talks
Bristol-Meyers Squibb (BMS) is reportedly having a hard time persuading its...
by Kim Yun-mi
|
2019-07-18 16:01
라인
Korean pulmonary arterial hypertension patients’ survival far lower than Japanese
The three-year survival rate of Korean patients with pulmonary arterial hyp...
by Kim Yun-mi
|
2019-07-15 16:48
라인
Humira permitted for nursing, pregnant patients
The local regulator allowed nursing and pregnant patients to use autoimmune...
by Kim Yun-mi
|
2019-07-11 16:41
라인
‘Patients with myeloproliferative neoplasm unaware of cause before diagnosis’
Most patients with a myeloproliferative neoplasm (MPN) were unaware of the ...
by Kim Yun-mi
|
2019-07-02 16:42
라인
BMS Korea files administrative suit to appeal Eliquis price cut
The price reduction of BMS Korea Pharmaceutical’s blood thinner Elidquis ha...
by Kim Yun-mi
|
2019-07-01 14:16
라인
Lilly anticipates Trulicity’s growth as GLP-1 receptor antagonists get popular
As physicians have increasingly recommended glucagon-like peptide-1 (GLP-1)...
by Kim Yun-mi
|
2019-06-28 16:12
라인
Why people still ask if AIDS is preventable
The government has granted insurance benefit to Gilead’s Truvada (tenofovir...
by Kim Yun-mi
|
2019-06-26 17:02
라인
‘Imbruvica raised survival rate of mantle cell lymphoma patients’
“Imbruvica works better than any other existing chemotherapy in relapsed an...
by Kim Yun-mi
|
2019-06-25 15:34
-
이전
11
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top